Light-activated cancer treatment uses tumour-targeting enzymes to cut side effects

A new two-component cancer therapy uses a modified enzyme to activate a light-sensitive prodrug compound, triggering cell death exclusively in cancerous cells when irradiated with a laser. The experimental treatment has already shown promise in mouse studies.